How to read this library

This is a reference guide to the blood tests, measurements and scores that come up in weight and metabolic care. For each one we use the same six-part frame, and one question dominates all of them.

• What it measures — the biology behind the number.
• Why it matters — what it's actually a marker of.
• When it's genuinely useful — the situations where it earns its place.
• How to interpret it — qualitative ranges and the caveats that undo a naïve reading. (Lab "normal ranges" vary between laboratories; we describe direction and meaning, not fixed numbers, except where a value is a formal diagnostic definition.)
• Common misconceptions — the beliefs that lead people astray.
• Does it change management? — the one that matters. A test you order out of habit, that returns "abnormal-ish," and that doesn't alter the plan, has mostly bought you cost, false positives and anxiety.

Our editorial position, stated once up front: more testing is not better care. The best evaluation is targeted — measure adiposity properly, screen for the harms obesity does, check the thyroid once, and reserve deeper testing for people whose story points there. That is the "TEST what matters" step of our method. → How Obesity Should Be Evaluated · The W8Experts Clinical Approach

A skeptical note on commercial "functional-medicine" and "metabolic reset" panels

Before the individual tests, the callout that frames all of them.

THE LIBRARY

Each entry: what it measures · why it matters · when it's useful · how to interpret · misconceptions · does it change management (skeptical).

LAB 1 · Haemoglobin A1c (HbA1c) — Grade A 🟢

What it measures. The percentage of haemoglobin that has glucose attached, reflecting average blood glucose over roughly the preceding two to three months (the lifespan of red cells). One blood draw, no fasting required.

Why it matters. It's the single highest-value metabolic test in weight care. It screens for prediabetes and type 2 diabetes — conditions obesity drives and that reframe the entire goal of treatment (prevention, and in some cases remission). It also helps choose therapy: a GLP-1 or GLP-1/GIP agent, for instance, addresses weight and glycaemia together. → Obesity & Diabetes

When it's genuinely useful. In essentially every adult weight evaluation, and for tracking response over time. It's more convenient than fasting glucose (no fasting) and less variable day to day.

How to interpret it. The diagnostic definitions are standardized: ≥6.5% = diabetes; 5.7–6.4% = prediabetes; <5.7% = normal (confirm diabetes with repeat or a second test). Caveats matter: anything that changes red-cell turnover distorts A1c — anaemia, iron deficiency, recent blood loss or transfusion, pregnancy, haemoglobin variants, chronic kidney or liver disease. In those settings A1c can read falsely high or low, and fasting glucose or other measures are needed.

Common misconceptions. - "A1c measures my sugar right now." No — it's a rolling average, not a snapshot. - "A normal A1c means my metabolism is fine." It's reassuring for glycaemia, but insulin resistance, dyslipidaemia and fatty liver can exist with a normal A1c. - "A1c is a weight test." It isn't; it's a glucose test that happens to be highly relevant to people with obesity.

Does it change management? Yes — routinely. Finding prediabetes or diabetes changes goals, monitoring and drug selection, and reframes weight loss as risk reduction rather than a cosmetic aim. This is one of the few tests that reliably alters the plan. Grade A 🟢

LAB 2 · Fasting plasma glucose — Grade A 🟢

What it measures. Blood glucose after an overnight (≥8 h) fast — a single-moment measure of glucose handling in the fasted state.

Why it matters. Like A1c, it screens for prediabetes and diabetes. It's cheap, universal and complementary: occasionally A1c and fasting glucose disagree, and having both clarifies borderline cases.

When it's genuinely useful. As part of the metabolic screen, and specifically when A1c may be unreliable (haemoglobin variants, altered red-cell turnover). An oral glucose tolerance test is reserved for selected situations (e.g., pregnancy, or when suspicion is high but A1c/fasting glucose are equivocal).

How to interpret it. Standard definitions: ≥126 mg/dL (7.0 mmol/L) = diabetes; 100–125 mg/dL (5.6–6.9 mmol/L) = impaired fasting glucose (prediabetes); <100 mg/dL = normal — confirmed on repeat for a diagnosis. Requires a true fast; a "fasting" sample that wasn't changes everything.

Common misconceptions. - "One high fasting glucose means I'm diabetic." A single value needs confirmation; stress, illness and a non-fast can elevate it. - "Normal fasting glucose rules out diabetes." Not entirely — some people have normal fasting values but abnormal A1c or post-meal glucose.

Does it change management? Yes, in the same way as A1c — it's a diagnostic screen that reframes goals and treatment. Between the two, A1c is usually the more practical first test; fasting glucose earns its keep as confirmation and in A1c-unreliable settings. Grade A 🟢

LAB 3 · Fasting insulin & HOMA-IR — Grade C 🟠 (read the skepticism)

What it measures. Fasting insulin is the circulating insulin level after an overnight fast. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a formula combining fasting insulin and fasting glucose to estimate insulin resistance.

Why it matters — and why to be cautious. Insulin resistance is real and central to metabolic disease. But the measurement of it by fasting insulin/HOMA-IR is far shakier than its popularity suggests. Fasting insulin assays are not well standardized between labs; the value is biologically noisy day to day; and there is no agreed cutoff that reliably changes what a clinician does for an individual. It is a research and epidemiology tool that has been marketed to patients as a personal "why you can't lose weight" number.

When it's genuinely useful. Rarely, in routine weight care. It has occasional value in specific evaluations (e.g., research, some PCOS or rare-syndrome contexts, unexplained hypoglycaemia work-ups) — but as a general screen for insulin resistance in obesity it mostly restates what waist circumference, triglycerides, HDL, A1c and blood pressure already tell you, more cheaply and reliably. → How Obesity Should Be Evaluated

How to interpret it. Qualitatively: higher fasting insulin and higher HOMA-IR suggest more insulin resistance, but assay variability and the lack of a validated action threshold mean a single number should not be over-read. Clinical markers of insulin resistance — central adiposity, high triglycerides, low HDL, hypertension, prediabetes, fatty liver — are more reliable and more actionable than the insulin value itself.

Common misconceptions. - "My HOMA-IR proves my metabolism is broken." It estimates a physiological state that is better captured by the metabolic-syndrome cluster; a number doesn't prove a broken metabolism. - "I need to get my fasting insulin down to lose weight." You don't treat the insulin number; you treat adiposity and metabolic risk, and the number follows. - "A normal fasting insulin means I'm metabolically healthy." Not necessarily — it's too noisy to reassure on its own.

Does it change management? Usually not. For the great majority of people, fasting insulin/HOMA-IR does not alter the plan beyond what standard metabolic markers already dictate — and it is a favourite of commercial panels precisely because it sounds explanatory. We generally advise against ordering it as a routine weight-loss test. Grade C 🟠 (limited/clinically uncertain for this purpose) → the functional-medicine callout above

LAB 4 · Lipid panel (total, LDL, HDL cholesterol) — Grade A 🟢

What it measures. A fasting or non-fasting panel reporting total cholesterol, LDL ("bad") cholesterol, HDL ("good") cholesterol, and (see next entry) triglycerides. Non-HDL cholesterol (total minus HDL) is often the most useful single number.

Why it matters. Dyslipidaemia clusters with visceral adiposity and is a direct, modifiable driver of cardiovascular risk — the leading cause of death in obesity and in metabolic (fatty) liver disease. → Obesity & Cardiovascular Health · MASLD & Cardiovascular Risk

When it's genuinely useful. In essentially every adult metabolic evaluation, for risk estimation and to decide whether lipid-lowering therapy is warranted alongside weight management.

How to interpret it. Interpretation is risk-based, not a single universal cutoff: the LDL/non-HDL target depends on overall cardiovascular risk (existing disease, diabetes, other factors). A pattern of high triglycerides with low HDL is the classic "metabolic" dyslipidaemia of insulin resistance. Weight loss, and some weight medications, tend to improve the picture — but lipids often need their own treatment regardless of weight.

Common misconceptions. - "If I lose weight my cholesterol will fix itself, so I don't need to check." Sometimes it improves; often high-risk LDL still needs treatment. Screening is the point. - "Dietary cholesterol is the main driver of my LDL." For most people the relationship is weaker than assumed; overall diet pattern, genetics and metabolic state matter more.

Does it change management? Yes. It directly informs cardiovascular-risk treatment decisions independent of the scale. This is a keep-it test. Grade A 🟢

LAB 5 · Triglycerides — Grade A 🟢

What it measures. The concentration of triglyceride fats in the blood, ideally fasting (they rise substantially after meals).

Why it matters. Triglycerides are among the most weight- and insulin-sensitive lab values. High triglycerides mark insulin resistance and metabolic dysfunction, contribute to cardiovascular risk, and — when very high — carry a distinct risk of pancreatitis.

When it's genuinely useful. As part of the lipid panel in every metabolic evaluation; particularly informative for tracking metabolic improvement, because they often fall quickly with weight loss, reduced refined-carbohydrate and alcohol intake, and glycaemic control.

How to interpret it. Qualitatively: normal → borderline → high → very high. Modestly raised triglycerides usually reflect diet, alcohol, and insulin resistance and respond to lifestyle and weight loss. Very high levels (the range associated with pancreatitis risk) are a distinct, more urgent problem needing specific management. Because they swing with the last meal and alcohol, a single non-fasting spike can mislead.

Common misconceptions. - "Triglycerides are just another cholesterol number." They behave differently — far more responsive to carbohydrate, alcohol and short-term weight change. - "Only very high triglycerides matter." Moderately high levels still flag metabolic risk even if they aren't in the pancreatitis range.

Does it change management? Often, yes — a genuinely useful and responsive marker. Modest elevations reinforce lifestyle and weight targets and track progress; very high levels change management directly (specific therapy, alcohol and carbohydrate reduction, pancreatitis-risk mitigation). Grade A 🟢

LAB 6 · ALT (alanine aminotransferase) — Grade B 🟡

What it measures. An enzyme concentrated in liver cells that leaks into the blood when hepatocytes are injured. ALT is the more liver-specific of the common "liver enzymes."

Why it matters. In weight and metabolic care, ALT is chiefly a clue to metabolic (dysfunction-associated) fatty liver disease (MASLD). But its central limitation matters: ALT measures injury, not fat and not scar. Significant fatty liver — and even advanced fibrosis — can exist with an entirely normal ALT. → "My Liver Tests Are Normal…" (/fatty-liver/normal-enzymes)

When it's genuinely useful. As a routine screen that, when elevated, raises suspicion of liver disease and prompts further evaluation. It is also an input to the FIB-4 score (see Lab 20). But a normal ALT must never be treated as an all-clear for the liver.

How to interpret it. Direction over precision: a raised ALT warrants explanation (fatty liver, alcohol, medications, viral hepatitis, other causes). Note that many laboratories' "upper limit of normal" is set higher than the thresholds hepatologists consider truly normal, so "normal" ALT can be falsely reassuring. The decisive move is not to fixate on the enzyme but to assess fibrosis risk. → Do I Have Fatty Liver?

Common misconceptions. - "Normal ALT means my liver is healthy." The single most important myth this site corrects — it does not exclude MASLD or fibrosis. - "A mildly high ALT means serious liver damage." Not necessarily; it means investigate, most commonly finding fatty liver, not scarring.

Does it change management? Sometimes. An elevated ALT usefully triggers a fibrosis-risk assessment (FIB-4, then elastography if indicated). But because normal enzymes don't exclude disease and mild elevations are common and non-specific, ALT alone rarely settles anything — the fibrosis question drives management, not the enzyme. That's why we grade its standalone usefulness B, not A. Grade B 🟡 → FIB-4 Explained (/fatty-liver/fib-4)

LAB 7 · AST (aspartate aminotransferase) — Grade B 🟡

What it measures. An enzyme found in the liver but also in muscle, heart and red blood cells; released with injury to any of those tissues, so it is less liver-specific than ALT.

Why it matters. AST complements ALT. The AST:ALT ratio carries information — a ratio that rises (AST exceeding ALT) can accompany more advanced liver fibrosis or point toward alcohol-related injury. AST is also a component of the FIB-4 score.

When it's genuinely useful. Alongside ALT in the standard panel, and specifically as a FIB-4 input. On its own it's rarely ordered for weight care.

How to interpret it. Because AST comes from muscle and other tissues too, an isolated elevation can reflect exercise, muscle injury or haemolysis rather than the liver — a real trap. Interpret it with ALT, the clinical story, and the AST:ALT pattern rather than in isolation.

Common misconceptions. - "High AST always means liver damage." Not always — strenuous exercise, muscle injury and a blood-sample artefact (haemolysis) can raise it. - "AST and ALT are interchangeable." They aren't; ALT is more liver-specific, and their ratio is the informative part.

Does it change management? Indirectly. Its main value is as part of the AST:ALT pattern and the FIB-4 calculation — which can change management by directing fibrosis assessment. As a solo test it seldom does. Grade B 🟡

LAB 8 · TSH & thyroid tests — Grade A 🟢 (check once; interpret soberly)

What it measures. TSH (thyroid-stimulating hormone) is the pituitary's signal to the thyroid and the best first-line screen for thyroid function; a high TSH suggests an underactive thyroid, a low TSH an overactive one. Free T4 (and sometimes free T3, antibodies) are added when TSH is abnormal or the picture warrants.

Why it matters. Hypothyroidism is common, easy to check, and genuinely treatable — so it belongs in the weight evaluation. But expectations must be calibrated: untreated hypothyroidism causes only modest weight gain, much of it fluid, and a normal TSH effectively rules it out as a major driver of significant obesity. Treating a normal thyroid does not produce weight loss.

When it's genuinely useful. A one-time TSH is reasonable in most weight evaluations. Repeat or expand testing (free T4, antibodies) when TSH is abnormal, when there are symptoms, or in known thyroid disease. For the full thyroid picture — Hashimoto's, antibodies, subclinical disease, treatment — see our sister site. → Thyroid & weight (Hashiexperts)

How to interpret it. A normal TSH is the common, reassuring result and largely closes the thyroid question for weight. Mildly abnormal ("subclinical") values are frequently transient or clinically unimportant and should not be over-treated in pursuit of weight loss. "Reverse T3" and salivary thyroid panels marketed by wellness services are not validated for this and should be avoided.

Common misconceptions. - "My weight must be my thyroid." Rarely, if TSH is normal — the most common thyroid myth in weight care. - "Optimizing a normal thyroid will help me lose weight." It won't; thyroid hormone is not a weight-loss treatment and carries real harm when misused. - "I need reverse T3 tested." Not for this — it's not a validated, actionable test here.

Does it change management? Occasionally, and worth the one check. When it uncovers genuine hypothyroidism, treatment matters (for health broadly, with modest weight effect). Far more often it returns normal and changes management by closing a door — sparing the patient a fruitless hunt and reframing the conversation. That reassurance value is why we still grade the single check A. Grade A 🟢 → Obesity & Hormones

LAB 9 · Testosterone (men) — Grade B 🟡 (targeted, not routine)

What it measures. Total testosterone (and, when needed, free testosterone plus SHBG, LH/FSH) — the principal male sex-hormone axis. Best drawn in the morning, when levels peak, and confirmed on a repeat before acting.

Why it matters. The relationship with weight is bidirectional and often misunderstood. Excess visceral fat lowers testosterone (partly via conversion to oestrogen and suppression of the axis), and weight loss frequently raises it. So a low reading in a man with obesity is often a consequence of the adiposity, not an independent disease — and testosterone is not a weight-loss treatment.

When it's genuinely useful. When a man has genuine symptoms of hypogonadism (low libido, erectile dysfunction, fatigue, loss of morning erections, reduced muscle) — then measure, confirm, and evaluate the cause. Screening asymptomatic men with obesity by reflex is low-yield and generates findings that resolve with weight loss. → Men's Health & Obesity

How to interpret it. Morning sample, repeated if low; interpret with SHBG (obesity lowers SHBG, which lowers total testosterone while free testosterone may be better preserved) and with LH/FSH to distinguish primary from secondary causes. A single low total testosterone in an obese man, without symptoms, rarely means what patients fear.

Common misconceptions. - "Low testosterone is why I gained weight, and TRT will fix it." Usually the causality runs the other way; testosterone therapy is not a weight-loss drug and carries its own risks and monitoring. - "Every man with obesity should have testosterone checked." No — test when symptomatic.

Does it change management? Sometimes — in symptomatic men. It can identify treatable hypogonadism and shape care, but for weight specifically the more effective move is often to treat the obesity and re-measure. Reflex testing in asymptomatic men rarely changes anything useful. Grade B 🟡 → Men's hormones (TestoExperts — forthcoming)

LAB 10 · Estradiol / oestrogen (women, and men) — Grade C 🟠 (rarely a weight test)

What it measures. Estradiol, the main oestrogen. In women it fluctuates dramatically across the menstrual cycle and falls at menopause; in men it derives largely from conversion of testosterone in fat tissue.

Why it matters. Oestrogen influences fat distribution — its decline at menopause shifts fat toward the abdomen and changes body composition — which is why menopause is a real inflection point for weight. But a blood estradiol level is a poor and rarely necessary tool for managing weight. The menopausal transition is diagnosed clinically (symptoms, cycle history), not by chasing a fluctuating oestrogen number.

When it's genuinely useful. In specific reproductive-endocrine contexts (fertility work-ups, evaluating amenorrhoea, monitoring certain therapies) — not as a routine weight test. For midlife weight change and hormone therapy, the relevant evaluation is clinical. → Menopause & Weight (MenoExperts)

How to interpret it. In premenopausal women the value is almost meaningless without knowing the cycle day; a single reading is easily misread. In men, a mildly elevated estradiol is usually a downstream effect of adiposity, not a primary problem.

Common misconceptions. - "My oestrogen level explains my menopausal weight gain and needs correcting to a target." Menopausal body-composition change is real, but a target estradiol number is not how it's managed. - "Men should routinely check and 'block' oestrogen for weight." Not supported; this is a common supplement- and clinic-marketing claim.

Does it change management? Usually not, for weight. Outside defined reproductive-endocrine indications, an estradiol level rarely alters the weight plan. The menopause conversation — including whether hormone therapy is appropriate for symptoms — is clinical, and belongs with our menopause resource. Grade C 🟠 → Obesity & Hormones

LAB 11 · Cortisol — Grade B 🟡 (only when the picture fits)

What it measures. Cortisol, the principal stress/glucocorticoid hormone. Measured by morning serum cortisol, an overnight dexamethasone-suppression test, late-night salivary cortisol, or 24-hour urinary free cortisol — the test chosen matters as much as the result.

Why it matters. True cortisol excess — Cushing's syndrome — causes central weight gain and is important and treatable. But it is uncommon, and central obesity on its own is a poor predictor of it. Routine cortisol testing for ordinary obesity is low-yield and generates false positives, because cortisol rises with stress, illness, depression, alcohol and obesity itself ("pseudo-Cushing" states).

When it's genuinely useful. When the clinical picture fits Cushing's: rapid central weight gain with purple striae, easy bruising, thin skin, proximal muscle weakness, and difficult-to-control hypertension or diabetes. Then a proper screening test (e.g., overnight dexamethasone suppression, late-night salivary cortisol, or 24-h urinary free cortisol) is warranted — a random daytime cortisol is not a useful screen. → When Weight Change Is a Red Flag

How to interpret it. Cortisol has a strong daily rhythm, so timing and test type are everything; abnormal screens need confirmation because false positives are common in obesity, stress and depression. This is a test to interpret with an endocrinologist, not a calculator.

Common misconceptions. - "My belly fat proves I have a cortisol/stress problem." Central fat alone doesn't diagnose Cushing's; the specific physical signs do. - "'Adrenal fatigue' is causing my weight." "Adrenal fatigue" is not a recognized diagnosis, and the salivary-cortisol panels sold to diagnose it are not valid. Grade E ⚫

Does it change management? Rarely — but decisively when it does. In the small minority with genuine Cushing's, identifying it transforms care. As a routine weight test it changes nothing and misleads often. Test only when the story points there. Grade B 🟡 (targeted use) → the functional-medicine callout above

LAB 12 · Renal function (creatinine, eGFR, electrolytes, urine albumin) — Grade A 🟢

What it measures. Kidney function and status: serum creatinine and the estimated glomerular filtration rate (eGFR) derived from it, electrolytes, and urine albumin (a marker of early kidney damage).

Why it matters. Obesity, diabetes and hypertension are leading causes of chronic kidney disease, and the kidney is both a target of metabolic disease and a gatekeeper for treatment. Several weight and diabetes medications require an adequate eGFR or are dosed by kidney function, so this test carries direct safety and prescribing consequences.

When it's genuinely useful. In the baseline metabolic evaluation, before and during certain drug therapies, and to screen for diabetic/hypertensive kidney disease (urine albumin-to-creatinine ratio is an early, high-value marker).

How to interpret it. eGFR estimates filtration; a falling eGFR or rising urine albumin signals kidney disease and changes both risk and treatment options. Creatinine is influenced by muscle mass, so very muscular or very low-muscle individuals can have eGFR estimates that mislead. Acute changes (dehydration, illness) can transiently shift values.

Common misconceptions. - "Kidney tests aren't relevant to weight." They are — for comorbidity screening and for safe medication choice. - "Normal creatinine means my kidneys are perfect." Early kidney disease often shows first as albumin in the urine, with normal creatinine.

Does it change management? Yes. It screens for a major obesity/diabetes complication and directly governs the safety and dosing of several treatments. A clear keep-it test. Grade A 🟢 → Obesity & Diabetes

LAB 13 · Vitamin D (25-hydroxyvitamin D) — Grade C 🟠

What it measures. 25-hydroxyvitamin D, the storage form used to assess vitamin D status.

Why it matters — with caution. Low vitamin D is statistically common in obesity, partly because it distributes into fat tissue (a dilution/sequestration effect), so a low level is often a marker of higher adiposity rather than a cause of it. There is no persuasive evidence that correcting vitamin D produces weight loss. Its relevance is to bone and general health, not to the number on the scale.

When it's genuinely useful. When there's a specific reason — bone health concerns, malabsorption, after bariatric surgery (where deficiencies are expected and monitored), or symptomatic deficiency. As a reflex "weight-loss" test it is low-yield.

How to interpret it. Deficiency, insufficiency and sufficiency are defined qualitatively and thresholds are debated; mild "insufficiency" is extremely common and often over-treated. Correcting a genuine deficiency is reasonable for health; expecting it to move weight is not.

Common misconceptions. - "Low vitamin D is why I can't lose weight." The association runs largely the other way; supplementing it doesn't drive weight loss. Grade E ⚫ for the weight-loss claim. - "Everyone should be aggressively supplemented to a high target." Not supported; more is not better.

Does it change management? For weight, rarely. For general/bone health in a deficient person, correcting it is reasonable — but it does not change the weight plan. It's a defensible test with a specific reason and a poor routine "why can't I lose weight" test. Grade C 🟠 → Weight-Loss Supplements

LAB 14 · Ferritin & iron studies — Grade C 🟠 → B 🟡 (context-dependent)

What it measures. Ferritin reflects the body's iron stores — but it is also an acute-phase reactant that rises with inflammation. Iron studies (serum iron, transferrin/TIBC, transferrin saturation) round out the picture.

Why it matters. Two different, sometimes opposite, situations arise in metabolic patients. (1) Iron deficiency (often from menstrual loss, diet, or after bariatric surgery) is common and treatable and can cause fatigue mistaken for a "metabolic" problem. (2) Ferritin is frequently elevated in metabolic disease and fatty liver as a marker of inflammation ("dysmetabolic hyperferritinaemia") — which can be misread as iron overload.

When it's genuinely useful. When there's anaemia, fatigue, heavy menstrual bleeding, a restrictive diet, or a post-bariatric context; and to help interpret an unexplained high ferritin (usually inflammation, occasionally genuine iron overload/haemochromatosis warranting evaluation).

How to interpret it. A low ferritin reliably indicates iron deficiency. A high ferritin is trickier: in metabolic disease it usually reflects inflammation, not iron overload — transferrin saturation helps distinguish them. Don't diagnose iron overload from ferritin alone in someone with fatty liver.

Common misconceptions. - "High ferritin means iron overload / haemochromatosis." Usually it's metabolic inflammation, not iron overload — check transferrin saturation before alarm. - "Low ferritin isn't important if I'm not anaemic." Iron deficiency causes symptoms before anaemia and is worth correcting.

Does it change management? When directed, yes. Confirmed iron deficiency changes management (find the cause; treat). An isolated high ferritin in metabolic disease mostly changes management by prompting the right interpretation (inflammation) rather than a wrong one (unnecessary iron-overload work-up). As a reflex weight test it's low-value; with a reason, it's useful. Grade C 🟠 routine / B 🟡 when indicated.

LAB 15 · Vitamin B12 — Grade C 🟠 → B 🟡 (context-dependent)

What it measures. Serum vitamin B12, needed for red-cell production and nerve function.

Why it matters. B12 has little to do with body weight directly, but it becomes relevant in specific weight-care contexts: metformin use lowers B12 over time, and bariatric surgery (and restrictive eating) predisposes to deficiency. Deficiency causes fatigue and neurological symptoms that can be misattributed to "metabolism."

When it's genuinely useful. In people on long-term metformin, after bariatric surgery, with restrictive or vegan diets, or with unexplained anaemia or neurological symptoms. Not as a routine "weight-loss" test.

How to interpret it. Low B12 warrants replacement and a search for the cause; borderline-low values sometimes need ancillary testing (methylmalonic acid) to confirm true deficiency. Serum B12 has limitations at the low-normal margin.

Common misconceptions. - "B12 (or B12 injections/'skinny shots') boosts metabolism and causes weight loss." No — there's no weight-loss effect in people who aren't deficient; the "B12 shot for energy/weight" is a marketing claim. Grade E ⚫ for the weight-loss claim. - "Everyone should supplement B12." Only those deficient or at risk.

Does it change management? In the right context, yes — it changes management for people on metformin or after bariatric surgery, and for genuine deficiency. As a routine weight test in an unselected person, it rarely does. Grade C 🟠 routine / B 🟡 in metformin/post-surgical contexts. → Bariatric Surgery

LAB 16 · Uric acid — Grade C 🟠

What it measures. Serum uric acid, a breakdown product of purine metabolism cleared by the kidneys.

Why it matters. Uric acid rises with insulin resistance, adiposity, alcohol, fructose intake and reduced kidney clearance, so it associates with metabolic syndrome. Its clear clinical relevance is gout (and, less commonly, uric-acid kidney stones). Whether elevated uric acid independently causes metabolic or cardiovascular disease — versus merely marking it — remains debated, and treating an asymptomatic high level to improve metabolic health is not established.

When it's genuinely useful. When there's gout, a history of gout, or uric-acid stones — to guide management. As a routine metabolic-syndrome or weight test, its added value beyond the standard cluster is limited.

How to interpret it. Higher levels raise gout risk and track with metabolic dysfunction; but an asymptomatic elevation is common and, on current evidence, not a target to treat for weight or metabolic outcomes. Levels can rise transiently with rapid weight loss and certain diets.

Common misconceptions. - "High uric acid is a disease I must lower even without symptoms." Asymptomatic hyperuricaemia is generally not treated with medication for metabolic benefit. - "Uric acid is only about gout." It also reflects metabolic state — but that association rarely changes what you do.

Does it change management? Mostly only in gout/stones. For symptomatic disease it directs treatment; as a routine weight/metabolic screen it seldom changes the plan. Grade C 🟠

LAB 17 · hs-CRP (high-sensitivity C-reactive protein) — Grade C 🟠

What it measures. A sensitive marker of systemic inflammation produced by the liver. The "high-sensitivity" assay detects the low-grade inflammation relevant to cardiovascular and metabolic disease.

Why it matters. Obesity is a low-grade inflammatory state, and hs-CRP is elevated on average — reflecting adipose-tissue inflammation. It carries some cardiovascular-risk information and falls with weight loss. But it is non-specific: any infection, injury, recent illness or inflammatory condition raises it, and it rarely tells you something the rest of the risk picture didn't.

When it's genuinely useful. Occasionally, to refine cardiovascular risk in selected borderline cases. It is not a diagnostic test, not specific to any cause, and not a "weight-loss" or "metabolic-cause" test — despite featuring prominently on commercial panels.

How to interpret it. Broadly, higher hs-CRP tracks with more inflammation and cardiovascular risk, but a single value is easily confounded by any intercurrent illness; interpret cautiously and never from one reading. Very high values usually mean acute infection/inflammation, not chronic metabolic risk.

Common misconceptions. - "A high CRP pinpoints why I'm inflamed / can't lose weight." It's non-specific — it flags inflammation without naming a cause or a treatment. - "I should chase my CRP down with supplements." Not an evidence-based target; weight loss and treating cardiovascular risk lower it as a byproduct.

Does it change management? Occasionally, at the margins of cardiovascular-risk assessment; rarely in weight care. It seldom adds actionable information beyond standard risk factors, and it is a staple of functional-medicine panels precisely because it usually looks abnormal in obesity without implying a specific action. Grade C 🟠 → Obesity & Cardiovascular Health

LAB 18 · Body composition (DXA, BIA) — Grade B 🟡

What it measures. Not a blood test, but core to weight care. DXA (dual-energy X-ray absorptiometry) partitions the body into fat, lean soft tissue and bone, and can estimate visceral fat; BIA (bioelectrical impedance) estimates body-fat percentage by passing a small current through the body — convenient but sensitive to hydration and much noisier.

Why it matters. BMI can't distinguish fat from muscle or show where fat sits. Body composition adds that — especially valuable for tracking fat loss versus lean-mass loss during rapid weight loss (including on GLP-1/GIP therapy) and for identifying sarcopenic patterns. → BMI, Body Fat & Body Composition · GLP-1 & Muscle Loss

When it's genuinely useful. For tracking over time — particularly when muscle preservation is a concern during rapid loss — and in selected clinical questions (sarcopenia, athletes misclassified by BMI). It is not required for everyone, and a single scan in isolation can mislead.

How to interpret it. Read trends, not one snapshot, and match the modality to the question: DXA is the more accurate research-grade tool; BIA is convenient but hydration-dependent and device-variable. Note that "lean mass" on DXA includes water and organ mass — it is not a strength or muscle-function measurement, so a lean-mass number should never be equated with "muscle destroyed." Pair composition with function (strength, performance) where possible. → GLP-1 & Muscle Loss

Common misconceptions. - "A drop in DXA lean mass means the drug destroyed my muscle." Lean mass includes water and organ mass; interpret with strength/function and remember that protein plus resistance training protect muscle during loss. - "BIA scales are precise." They're convenient estimates, easily thrown off by hydration and the device used. - "Everyone needs a DXA." Useful for tracking, not mandatory.

Does it change management? Sometimes — for tracking and muscle-preservation decisions. It can prompt attention to protein and resistance training, or reassure that loss is mostly fat. But it's a monitoring aid, not a diagnostic gate, and a single reading rarely changes the plan by itself. Grade B 🟡

LAB 19 · Waist circumference (and waist-to-height ratio) — Grade A 🟢

What it measures. A tape-measure assessment of central adiposity. Waist-to-height ratio (keep your waist under half your height, as a simple rule of thumb) is an easy, reliable refinement.

Why it matters. Central/visceral fat — not total weight — drives most metabolic and cardiovascular risk. Waist captures information BMI misses, particularly in people at "normal" or "overweight" BMI who nonetheless carry high-risk visceral fat. It's cheap, needs no lab, and is among the highest-value measurements in the whole evaluation.

When it's genuinely useful. In essentially every weight and metabolic evaluation, and for tracking — waist often improves with visceral-fat loss even when the scale moves modestly. → How Obesity Should Be Evaluated

How to interpret it. Interpretation is threshold- and population-based: risk rises above sex-specific waist cut-points, and ethnicity-specific (lower) thresholds apply in South Asian and some other populations, where metabolic risk appears at lower waist and BMI. Measurement technique matters for consistency, so track it the same way each time.

Common misconceptions. - "Waist is too crude to bother with." The opposite — it's cheap and high-yield, adding independent risk information beyond BMI. - "If my BMI is normal, my waist doesn't matter." Central fat can carry real risk at a normal BMI.

Does it change management? Yes — quietly, often. It reclassifies risk (especially at normal/overweight BMI), sets a meaningful non-scale target, and tracks visceral-fat change. A simple measurement that genuinely informs the plan. Grade A 🟢 → BMI, Body Fat & Body Composition

LAB 20 · FIB-4 (Fibrosis-4 Index) — Grade A 🟢 (brief — full page linked)

What it measures. A calculated score, FIB-4 = (Age × AST) ÷ (Platelets × √ALT), that estimates the risk of advanced liver fibrosis from four routine values. It uses labs most people already have — no extra test, no cost.

Why it matters. In metabolic (fatty) liver disease the outcome that matters is fibrosis (scar), not fat — and FIB-4 is the guideline-recommended first step to decide who needs further fibrosis assessment. Its great strength is a reliable low-risk rule-out. Don't just find fat — find risk. → Do I Have Fatty Liver?

When it's genuinely useful. As the initial fibrosis-risk filter in anyone with, or at risk of, MASLD (obesity, type 2 diabetes, metabolic syndrome) — including people with normal liver enzymes, whose fibrosis risk enzymes alone would miss.

How to interpret it. Guideline cutoffs: <1.3 = low risk (strong rule-out); 1.3–2.67 = indeterminate (needs a second test, usually elastography); >2.67 = high risk (elastography and/or hepatology referral). Over age 65, raise the lower cutoff to ~2.0 to cut false positives, because age is in the numerator. A high score is a flag prompting the next test, not a diagnosis.

Common misconceptions. - "A high FIB-4 means I have cirrhosis." No — it raises probability enough to justify elastography; false positives are common, especially with age. - "Normal enzymes mean my FIB-4 will be fine." Not reliably — FIB-4 weights age and platelets too, which is the point.

Does it change management? Yes. It routes people to (or away from) elastography and referral, sparing the low-risk majority unnecessary testing while catching those who need it. One of the clearest management-changing tools in this library. Grade A 🟢 → FIB-4 Explained (/fatty-liver/fib-4)

LAB 21 · Liver stiffness / elastography (VCTE/FibroScan, MRE) — Grade A 🟢 / B 🟡 (brief — full page linked)

What it measures. A non-invasive physical measurement of liver stiffness as a surrogate for fibrosis. VCTE (FibroScan) reports stiffness in kilopascals and, via CAP, also estimates liver fat — two separate readings. MRE (MR elastography) is more accurate but costlier and less available.

Why it matters. It's the key second-line test after an indeterminate or high FIB-4, giving a far better estimate of fibrosis than enzymes or FIB-4 alone — and it keeps the distinction the whole liver story turns on: fat is not fibrosis. CAP measures fat; stiffness measures scar. → What Is MASLD?

When it's genuinely useful. When FIB-4 is indeterminate or high, to stratify fibrosis risk and decide on monitoring, intervention or referral; and to follow fibrosis/fat over time. Not needed for the low-risk majority ruled out by FIB-4.

How to interpret it. Higher stiffness (kPa) suggests more fibrosis, across broadly low → intermediate → high bands, but results can be confounded by acute inflammation, congestion, food intake, obesity and operator/probe factors — so a single value is interpreted with the clinical picture, not as a verdict. MRE is the more reliable (and more expensive) option when VCTE is unreliable or discordant.

Common misconceptions. - "FibroScan measures how much fat is in my liver." It measures stiffness (fibrosis surrogate); the separate CAP number estimates fat. - "A high stiffness reading is a diagnosis of cirrhosis." It's a strong indicator that raises or lowers probability; biopsy remains the selective reference standard when it matters. → Liver Biopsy: When It's Needed

Does it change management? Yes. It's often the study that determines whether someone is monitored, treated more intensively, or referred to hepatology — and it separates fat from fibrosis, which is the entire point of the MASLD workup. Grade A 🟢 (targeted use after FIB-4) → FibroScan & Elastography (/fatty-liver/elastography)

What the evidence says (about testing in weight care)

• What we know: A small, purposeful panel — glycaemia (A1c/glucose), lipids and triglycerides, liver enzymes with FIB-4, kidney function, a one-time TSH — reliably screens for the harms of obesity and changes management. Waist circumference is high-value and cheap.
• What we think: Body composition and elastography are useful tracking and stratification tools used selectively, not universal requirements. Deeper hormone testing (testosterone, cortisol, estradiol) belongs only when the clinical story points there.
• What we don't know: The single "optimal" panel; validated action thresholds for fasting insulin/HOMA-IR; body-composition cut-points that change outcomes for everyone.
• What patients should do: For each proposed test, ask the one question that governs this whole library — "Which decision would this result change?" If the honest answer is "none," reconsider the test. → The W8Experts Clinical Approach

Questions patients ask

KEEP READING

• How Obesity Should Be Evaluated — the workup this library supports: test what matters, skip what doesn't.
• When Weight Change Is a Red Flag — the secondary causes (and the specific findings) that justify deeper testing.
• FIB-4 Explained — the full guide to the fibrosis-risk score summarized here. (/fatty-liver/fib-4)
• FibroScan & Elastography — how liver stiffness is measured, and fat vs fibrosis. (/fatty-liver/elastography)
• Obesity & Hormones — which hormone tests change management, and which just cost money.
• Weight-Loss Supplements / Natural & Alternative Approaches — the marketing behind many "metabolic" panels and "boosters."

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: AASLD Practice Guidance on MASLD (2023) and FIB-4/elastography risk stratification; ADA Standards of Care (A1c/glucose diagnostic thresholds); guideline lipid/cardiovascular-risk frameworks; Endocrine Society guidance on obesity and secondary causes, thyroid, testosterone and Cushing's evaluation; laboratory-medicine caveats on A1c reliability, ferritin as an acute-phase reactant, and cortisol testing. Cross-references: Hashiexperts (thyroid), TestoExperts (men's hormones — forthcoming), MenoExperts (menopause). Educational only; not individualized medical advice, and not a diagnosis.